CIDARA THERAPEUTICS INC (CDTX) Stock Overview
USA - NASDAQ:CDTX - US1717572069 - Common Stock
CDTX Key Statistics, Chart & Performance
The current stock price of CDTX is 98.5 USD. In the past month the price increased by 51.88%. In the past year, price increased by 783.85%.
CDTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.34 | 417.90B | ||
| AMGN | AMGEN INC | 13.64 | 160.11B | ||
| GILD | GILEAD SCIENCES INC | 14.28 | 137.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.14 | 104.83B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.15 | 63.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.43B | ||
| ARGX | ARGENX SE - ADR | 85.39 | 48.45B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.03 | 41.03B | ||
| INSM | INSMED INC | N/A | 32.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.12B | ||
| BIIB | BIOGEN INC | 9.7 | 22.76B | ||
| NTRA | NATERA INC | N/A | 21.99B |
Related stock screener links
About CDTX
Company Profile
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Company Info
CIDARA THERAPEUTICS INC
6310 Nancy Ridge Dr Ste 101
San Diego CALIFORNIA 92121 US
CEO: Jeffrey Stein
Employees: 69
Phone: 18587526170
CIDARA THERAPEUTICS INC / CDTX FAQ
What is the stock price of CIDARA THERAPEUTICS INC today?
The current stock price of CDTX is 98.5 USD. The price increased by 2.24% in the last trading session.
What is the ticker symbol for CIDARA THERAPEUTICS INC stock?
The exchange symbol of CIDARA THERAPEUTICS INC is CDTX and it is listed on the Nasdaq exchange.
On which exchange is CDTX stock listed?
CDTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CIDARA THERAPEUTICS INC stock?
13 analysts have analysed CDTX and the average price target is 75.48 USD. This implies a price decrease of -23.37% is expected in the next year compared to the current price of 98.5. Check the CIDARA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CIDARA THERAPEUTICS INC worth?
CIDARA THERAPEUTICS INC (CDTX) has a market capitalization of 2.50B USD. This makes CDTX a Mid Cap stock.
How many employees does CIDARA THERAPEUTICS INC have?
CIDARA THERAPEUTICS INC (CDTX) currently has 69 employees.
What are the support and resistance levels for CIDARA THERAPEUTICS INC (CDTX) stock?
CIDARA THERAPEUTICS INC (CDTX) has a support level at 67.79. Check the full technical report for a detailed analysis of CDTX support and resistance levels.
Is CIDARA THERAPEUTICS INC (CDTX) expected to grow?
The Revenue of CIDARA THERAPEUTICS INC (CDTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CDTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CIDARA THERAPEUTICS INC (CDTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDTX, evaluating the profitability, health, valuation and growth aspects
- CIDARA THERAPEUTICS INC (CDTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CIDARA THERAPEUTICS INC (CDTX) Sales and EPS estimates to see what analysts future expectations are.
- CIDARA THERAPEUTICS INC (CDTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CIDARA THERAPEUTICS INC (CDTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CIDARA THERAPEUTICS INC (CDTX) Stock Chart to make your own analysis
- CIDARA THERAPEUTICS INC (CDTX) Latest news and press-releases to stay up to date.
Does CIDARA THERAPEUTICS INC (CDTX) stock pay dividends?
CDTX does not pay a dividend.
When does CIDARA THERAPEUTICS INC (CDTX) report earnings?
CIDARA THERAPEUTICS INC (CDTX) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of CIDARA THERAPEUTICS INC (CDTX)?
CIDARA THERAPEUTICS INC (CDTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.13).
What is the Short Interest ratio of CIDARA THERAPEUTICS INC (CDTX) stock?
The outstanding short interest for CIDARA THERAPEUTICS INC (CDTX) is 8.73% of its float. Check the ownership tab for more information on the CDTX short interest.
CDTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDTX. When comparing the yearly performance of all stocks, CDTX is one of the better performing stocks in the market, outperforming 99.39% of all stocks.
CDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CDTX. CDTX has a great financial health rating, but its profitability evaluates not so good.
CDTX Financial Highlights
Over the last trailing twelve months CDTX reported a non-GAAP Earnings per Share(EPS) of -11.13. The EPS decreased by -77.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.99% | ||
| ROE | -23.44% | ||
| Debt/Equity | 0 |
CDTX Forecast & Estimates
13 analysts have analysed CDTX and the average price target is 75.48 USD. This implies a price decrease of -23.37% is expected in the next year compared to the current price of 98.5.
For the next year, analysts expect an EPS growth of 46.61% and a revenue growth -100% for CDTX